Browsing category:

Immunological Agent


Impressive news dominated the headlines at the 56th American Society of Hematology annual meeting regarding anti-cancer powerhouse Pomalidomide. Results from a comprehensive study conducted by Celgene Corporation, the company that markets the brand name of Pomalidomide, POMALYST, were extremely encouraging. The trial, coined STRATUS, involved 599 patients suffering from refractory or relapsed multiple myeloma. Patients[…]

Read More

Reassuring findings were presented at the American Society of Hematology Annual Meeting at the beginning of December 2014 regarding the use of the immunomodulatory drug Lenalidomide. Concerns for patients with myelodysplastic syndrome (MDS) being administered this potent anti-cancer drug were quelled, when a comprehensive study revealed that this lifesaving treatment did not lead to a[…]

Read More

February 8, 2013 – Pomalidomide Now Approved by the FDA to Treat Multiple Myeloma under the FDA’s accelerated approval program. Pomalidomide therapy was also granted orphan product designation as it is intended to treat a rare disease.  Marketed as Pomalyst by Celgene, Pomalidomide, CAS 19171-19-8, is a last chance treatment for patients with Multiple Myeloma[…]

Read More

The Oncology segment of the pharmaceutical industry is not only a fast growing one, but it is also an area where shortages are anticipated. A decrease in availability of sterile injectable oncology drugs have been reported since 2007.  Furthermore, many of the sterile injectable oncology drugs that experienced shortages in 2010 and 2011 had a[…]

Read More

Glatiramer, CAS# 28704-27-0, and Glatiramer Acetate, CAS# 147245-92-9, are also known as Copaxone. In the spotlight recently, Copaxone’s patent is due to expire on May 24, 2014. The flurry of interest regarding Copaxone follows the devastating diagnosis of Multiple Sclerosis for beloved reality star Jack Osbourne. In mid June of 2012 reports surfaced about Jack’s[…]

Read More

For organ transplant patients, the normally protective immune response can threaten the longevity and function of the transplanted organ. Currently, organ transplant patients must take immunosuppressive or anti-rejection medication to prevent the immune system from fighting against the new, transplanted organ. Often a choice is made between the certain damage of a steroid drug, and[…]

Read More